Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Phase 2a Study of BMS-790052 in Combination With Peginterferon Alfa-2a (Pegasys®) and Ribavirin (Copegus®) in Treatment Naive Subjects With Chronic Hepatitis C Virus Genotype 1
Brief Summary: The purpose of this study is to identify 1 or more doses of daclatasvir, which when used in combination with pegylated interferon alpha and ribavirin, are safe and demonstrate sufficient anti-hepatitis C virus activity.


Options:
A: Arm Label: 2; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: BI 201335, Drug: BI 207127 | Arm Label: 1; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: BI 201335, Drug: Ribavirin | Arm Label: 3; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: BI 201335, Drug: Ribavirin | Arm Label: 4; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: Ribavirin, Drug: BI 201335 | Arm Label: 5; Type: EXPERIMENTAL; Interventions: Drug: BI 201335, Drug: BI 207127, Drug: Ribavirin | Arm Label: 6; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: BI 201335, Drug: BI 207217 | Arm Label: 7; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: BI 201335 | Arm Label: 8; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: Ribavirin, Drug: BI 201335 | Arm Label: 9; Type: EXPERIMENTAL; Interventions: Drug: BI 207127, Drug: BI 201335, Drug: Ribavirin | Arm Label: 10; Type: EXPERIMENTAL; Interventions: Drug: BI 201335, Drug: BI 207127, Drug: Ribavirin | Arm Label: 11; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: BI 207127, Drug: BI 201335 | Arm Label: 12; Type: EXPERIMENTAL; Interventions: Drug: Ribavirin, Drug: BI 201335, Drug: BI 207127 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 11 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 9 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 11 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 10 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 5 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 7 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 11 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 12 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 12 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 7 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 12 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 9 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 8 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 3 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 8 | Intervention Type: DRUG; Name: BI 207217; Assigned to Arm(s): 6 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 8 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 10 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 1 | Intervention Type: DRUG; Name: BI 207127; Assigned to Arm(s): 2 | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): 4 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 9 | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): 10
B: Arm Label: Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Peginterferon alpha-2a, Drug: ribavirin | Arm Label: Daclatasvir, Peginterferon alpha-2a, ribavirin (B); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Peginterferon alpha-2a, Drug: ribavirin | Arm Label: Daclatasvir, Peginterferon alpha-2a, ribavirin (C); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Peginterferon alpha-2a, Drug: ribavirin | Arm Label: Placebo, Peginterferon alpha-2a, ribavirin (D); Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon alpha-2a, Drug: ribavirin | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A) | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (B) | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (C) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Peginterferon alpha-2a, ribavirin (D) | Intervention Type: DRUG; Name: Peginterferon alpha-2a; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (B), Daclatasvir, Peginterferon alpha-2a, ribavirin (C), Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A), Placebo, Peginterferon alpha-2a, ribavirin (D) | Intervention Type: DRUG; Name: ribavirin; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (B), Daclatasvir, Peginterferon alpha-2a, ribavirin (C), Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A), Placebo, Peginterferon alpha-2a, ribavirin (D)
C: Arm Label: TMC435; Type: EXPERIMENTAL; Interventions: Drug: TMC435, Drug: Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b), Drug: Ribavirin (RBV) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b), Drug: Ribavirin (RBV) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo | Intervention Type: DRUG; Name: TMC435; Assigned to Arm(s): TMC435 | Intervention Type: DRUG; Name: Peginterferon alpha-2a or Peginterferon alpha-2b (PegIFNα-2a/b); Assigned to Arm(s): Placebo, TMC435 | Intervention Type: DRUG; Name: Ribavirin (RBV); Assigned to Arm(s): Placebo, TMC435
D: Arm Label: PegIFN/RBV; Type: ACTIVE_COMPARATOR; Interventions: Drug: PegIFN/RBV | Arm Label: BI 201335 for 12 or 24 weeks; Type: EXPERIMENTAL; Interventions: Drug: PegIFN/RBV, Drug: BI 201335 | Arm Label: Placebo and PegIFN/RBV; Type: ACTIVE_COMPARATOR; Interventions: Drug: PegIFN/RBV, Drug: Placebo | Intervention Type: DRUG; Name: PegIFN/RBV; Assigned to Arm(s): BI 201335 for 12 or 24 weeks, PegIFN/RBV, Placebo and PegIFN/RBV | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): BI 201335 for 12 or 24 weeks | Intervention Type: DRUG; Name: BI 201335; Assigned to Arm(s): BI 201335 for 12 or 24 weeks | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo and PegIFN/RBV

Answer: B